地塞米松使用对蛛网膜下腔出血后迟发性脑缺血及不良功能结局影响的倾向评分分析
本研究基于单中心蛛网膜下腔出血登记数据,纳入2010至2015年收治的309例动脉瘤性蛛网膜下腔出血患者,其中101例(33%)在发病7天内使用地塞米松递减方案。倾向评分分析显示,地塞米松使用与出院时不良功能结局显著降低相关(OR 0.35,95%CI 0.19-0.66),但与迟发性脑缺血(OR 0.93,95%CI 0.53-1.64)和感染(OR 0.60,95%CI 0.34-1.06)无显著关联。
要点
- 地塞米松使用与出院不良功能结局降低相关(OR 0.35,95%CI 0.19-0.66)。
- 地塞米松与迟发性脑缺血无显著关联(OR 0.93,95%CI 0.53-1.64)。
- 地塞米松与感染无显著关联(OR 0.60,95%CI 0.34-1.06)。
核心结论
- 控制地塞米松使用的预测因素后,动脉瘤性蛛网膜下腔出血后使用地塞米松与出院时不良功能结局降低相关,但与迟发性脑缺血无关。
研究设计与样本
- 单中心蛛网膜下腔出血登记研究,纳入2010至2015年收治的患者;感兴趣干预为发病7天内使用地塞米松递减方案。
- 共440例蛛网膜下腔出血患者入院,309例符合入选标准,其中101例(33%)使用地塞米松。
- 采用logistic回归模型计算地塞米松使用的倾向评分,纳入地塞米松使用和结局的潜在预测因素,并在分析中控制倾向评分。
主要发现
- 127例(41%)出院时改良Rankin量表评分>3分,105例(34%)发生迟发性脑缺血,94例(30%)发生感染。
- 倾向评分分析后,地塞米松使用与不良功能结局显著降低相关(OR 0.35,95%CI 0.19-0.66)。
- 地塞米松使用与迟发性脑缺血无显著关联(OR 0.93,95%CI 0.53-1.64)。
- 地塞米松使用与感染无显著关联(OR 0.60,95%CI 0.34-1.06)。
临床怎么用
- 作者认为,动脉瘤性蛛网膜下腔出血后使用地塞米松与出院时不良功能结局降低相关,但与迟发性脑缺血无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: An inflammatory response occurs after aneurysmal subarachnoid hemorrhage (aSAH) and predicts poor outcomes. Glucocorticoids suppress inflammation and promote fluid retention. Dexamethasone is often administered after aSAH for postoperative cerebral edema and refractory headache. Our objective was to examine the impact of dexamethasone use on functional outcomes and delayed cerebral ischemia (DCI) after aSAH. METHODS: Patients with aSAH admitted between 2010 and 2015 were included; the data source was a single-center subarachnoid hemorrhage registry. The intervention of interest was a dexamethasone taper used <7 days from ictus. The primary outcome was poor discharge functional outcome, with a modified Rankin Scale score >3. Other outcomes included DCI and infection. A propensity score for use of dexamethasone was calculated using a logistic regression model that included potential predictors of dexamethasone use and outcome. The impact of dexamethasone on outcomes of interest was calculated and the propensity score was controlled for. RESULTS: A total of 440 patients with subarachnoid hemorrhage were admitted during the study period and 309 met eligibility criteria. Dexamethasone was administered in 101 patients (33%). A total of 127 patients (41%) had a discharge modified Rankin Scale score >3, 105 (34%) developed DCI, and 94 (30%) developed an infection. After propensity score analysis, dexamethasone use was associated with a significant reduction in poor functional outcomes (odds ratio [OR], 0.35; 95% confidence interval [CI], 0.19-0.66) but showed no significant association with DCI (OR, 0.93; 95% CI, 0.53-1.64) or infection (OR, 0.60; 95% CI, 0.34-1.06). CONCLUSIONS: Dexamethasone use after aSAH was associated with a reduction in poor functional outcomes at discharge but not DCI, controlling for predictors of dexamethasone use.
引用
- Mohney N, Williamson CA, Rothman E, et al. A Propensity Score Analysis of the Impact of Dexamethasone Use on Delayed Cerebral Ischemia and Poor Functional Outcomes After Subarachnoid Hemorrhage. World Neurosurg. 2017. PMID: 29061461. doi:10.1016/j.wneu.2017.10.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。